Kadmon to Present Clinical and Preclinical Data Highlighting the Role
of ROCK2 Signaling in Immune System Function at AAI Annual Meeting

-- Data Provide Further Support for ROCK2 as a Therapeutic Target for
Autoimmune Disease --

May 11, 2017 09:00 AM Eastern Daylight Time

NEW YORK--(BUSINESS WIRE)--Kadmon Holdings, Inc. (NYSE:KDMN) (“Kadmon” or the “Company”) today
announced the presentation of data from its completed Phase 2 clinical
trial of KD025, the Company’s oral Rho-associated coiled-coil kinase 2
(“ROCK2”) inhibitor, in patients with moderate to severe psoriasis, as
well as new preclinical data demonstrating the importance of ROCK2
signaling in regulating the pro-inflammatory aspect of immune response.
The data will be presented in oral and poster presentations at the
American Association of Immunologists (AAI) Annual Meeting, taking place
May 12-16, 2017, in Washington, D.C.

“The data from these studies provide further support for ROCK2
inhibition as a therapeutic approach in autoimmune diseases,” said
Alexandra Zanin-Zhorov, PhD, Vice President, Head of Immunology at
Kadmon and a lead author on the studies. “ROCK2 signaling represents an
important target in autoimmunity, as it regulates STAT3 phosphorylation
and transcriptional activity in human T cells, both key contributors to
autoimmune conditions.”

“The findings from our completed Phase 2 study of KD025 in psoriasis,
which were recently published in the Journal of Immunology,
together with the new mechanistic preclinical data, underscore the
importance of ROCK2 signaling in controlling auto-aggressive immune
responses and support the clinical development of KD025 in autoimmune
indications,” said Harlan W. Waksal, President and Chief Executive
Officer at Kadmon. “We remain enthusiastic about KD025’s therapeutic
potential in autoimmunity and we look forward to announcing data from
our ongoing Phase 2 trials in chronic graft-versus-host disease and in
moderate to severe psoriasis in the second half of this year.”

The new preclinical data describe the mechanism by which ROCK2 mediates
activation of STAT3, a key regulator of the inflammatory pathway, and
subsequent transcriptional activity during the induction of
pro-inflammatory T cells. Specifically, researchers demonstrated that
ROCK2 binds to STAT3 and regulates the transcription of specific genes
that control pro-inflammatory T helper 17 (Th17) cell and T follicular
helper (Tfh) cell function. These findings highlight the importance of
ROCK2 signaling in controlling auto-aggressive immune responses.

About Kadmon Holdings, Inc.

Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company
focused on developing innovative products for significant unmet medical
needs. We have a diversified product pipeline in autoimmune and fibrotic
diseases, oncology and genetic diseases.

Safe Harbor Statement

This press release contains forward-looking statements. Such statements
may be preceded by the words “may,” “will,” “should,” “expects,”
“plans,” “anticipates,” “could,” “intends,” “targets,” “projects,”
“contemplates,” “believes,” “estimates,” “predicts,” “potential” or
“continue” or the negative of these terms or other similar expressions.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the
forward-looking statements. We believe that these factors include, but
are not limited to, (i) the initiation, timing, progress and results of
our preclinical studies and clinical trials, and our research and
development programs; (ii) our ability to advance product candidates
into, and successfully complete, clinical trials; (iii) our reliance on
the success of our product candidates; (iv) the timing or likelihood of
regulatory filings and approvals; (v) our ability to expand our sales
and marketing capabilities; (vi) the commercialization of our product
candidates, if approved; (vii) the pricing and reimbursement of our
product candidates, if approved; (viii) the implementation of our
business model, strategic plans for our business, product candidates and
technology; (ix) the scope of protection we are able to establish and
maintain for intellectual property rights covering our product
candidates and technology; (x) our ability to operate our business
without infringing the intellectual property rights and proprietary
technology of third parties; (xi) costs associated with defending
intellectual property infringement, product liability and other claims;
(xii) regulatory developments in the United States, Europe and other
jurisdictions; (xiii) estimates of our expenses, future revenues,
capital requirements and our needs for additional financing; (xiv) the
potential benefits of strategic collaboration agreements and our ability
to enter into strategic arrangements; (xv) our ability to maintain and
establish collaborations or obtain additional grant funding; (xvi) the
rate and degree of market acceptance of our product candidates; (xvii)
developments relating to our competitors and our industry, including
competing therapies; (xviii) our ability to effectively manage our
anticipated growth; (xix) our ability to attract and retain qualified
employees and key personnel; (xx) our ability to achieve cost savings
and other benefits from our efforts to streamline our operations and to
not harm our business with such efforts; and (xxi) the use of proceeds
from our recent private placement. More detailed information about
Kadmon and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's filings with
the U.S. Securities and Exchange Commission (SEC), including the
Company's Annual Report on Form 10-K filed pursuant to Section 13 of the
Securities Exchange Act of 1934, as amended, with the SEC on March 22,
2017. Investors and security holders are urged to read these documents
free of charge on the SEC's web site at www.sec.gov.
The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events
or otherwise.